Hale G, Dyer M J, Clark M R, Phillips J M, Marcus R, Riechmann L, Winter G, Waldmann H
Department of Pathology, University of Cambridge.
Lancet. 1988 Dec 17;2(8625):1394-9. doi: 10.1016/s0140-6736(88)90588-0.
A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients with non-Hodgkin lymphoma. Doses of 1-20 mg daily were given intravenously for up to 43 days. In both patients lymphoma cells were cleared from the blood and bone marrow and splenomegaly resolved. One patient had lymphadenopathy which also resolved. These effects were achieved without myelosuppression, and normal haemopoeisis was restored during the course of treatment, partially in one patient and completely in the other. No antiglobulin response was detected in either patient. CAMPATH-1H is a potent lympholytic antibody which might have an important use in the treatment of lymphoproliferative disorders and additionally as an immunosuppressive agent.
一种经过基因改造的人IgG1单克隆抗体（CAMPATH-1H）被用于治疗两名非霍奇金淋巴瘤患者。每日静脉注射剂量为1至20毫克，持续时间长达43天。两名患者的淋巴瘤细胞均从血液和骨髓中清除，脾肿大也得到缓解。其中一名患者的淋巴结病也得到缓解。这些效果在没有骨髓抑制的情况下实现，并且在治疗过程中正常造血功能得以恢复，一名患者部分恢复，另一名患者完全恢复。两名患者均未检测到抗球蛋白反应。CAMPATH-1H是一种强效的溶淋巴细胞抗体，可能在治疗淋巴增殖性疾病以及作为免疫抑制剂方面具有重要用途。
